SEC Filing Analysis: Vaxart, Inc. (VXRT)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Vaxart appointed retired Vice Admiral Dr. Raquel C. Bono to its Board of Directors pursuant to a shareholder cooperation agreement.
• Market Impact: Neutral; standard corporate governance update with no direct open-market transactions or immediate capital structure shifts.

Company Information

Field	Value
Company	Vaxart, Inc.
Ticker Symbol	VXRT
CIK	0000072444
Industry	Biological Products (No Diagnostic Substances)

Insider Information

Field	Value
Name	Raquel C. Bono, M.D., M.B.A., FACS
CIK	null
Title/Position	Independent Director
Relationship	Director

Transaction Details

Field	Value
Form Type	8-K (Item 5.02, Item 7.01)
Transaction Date	October 16, 2026
Transaction Code	null
Security Type	Common Stock (Eligible for standard director equity awards)
Shares Involved	null
Price Per Share	null
Total Value	null
Shares Owned After	null
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00 (Governance Appointment)
% of Market Cap	0.00%
Shares Transacted	0
% of Shares Outstanding	0.00%
Post-Transaction Ownership	N/A
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With Vaxart's market capitalization at approximately $110 million and 241.97 million shares outstanding, board appointments carry no immediate balance sheet or market valuation changes.
• Dilution Impact: Dr. Bono will receive standard non-employee director compensation (cash and equity grants under the existing plan). Any forthcoming initial equity awards are expected to be immaterial relative to the 241.97M shares outstanding (<0.05% dilution).
• Governance Context: Dr. Bono was appointed pursuant to the cooperation agreement executed in July 2026 between Vaxart and an investor group. She will chair the newly created Stockholder Engagement Committee.

Market Impact Analysis

• Stock Impact Direction: Neutral
• Reasoning: The 8-K reflects planned governance execution following a shareholder agreement rather than unanticipated operational changes or material capital events.
• Expected Volume Impact: Negligible trading volume impact anticipated.
• Sentiment Indicator: Neutral

Additional Context

• Board Qualifications: Dr. Bono served as Director of the Defense Health Agency (overseeing a $50B healthcare enterprise), Director of Washington State's COVID-19 Health System Response, and currently serves on the board of Humana Inc. (NYSE: HUM).
• Regulatory Item: Disclosed under Item 5.02 (Departure/Election of Directors) and Item 7.01 (Regulation FD Disclosure).